Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients

The use of monoclonal antibodies (mAbs) in the clinic has successfully expanded to treatment of cancer, viral infections, inflammations, and other indications. However, some of the classes of mAbs that are used in the clinic show the formation of anti-drug antibodies (ADAs) leading to loss of effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosch, Romy, Guchelaar, Henk-Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249215/
https://www.ncbi.nlm.nih.gov/pubmed/35784343
http://dx.doi.org/10.3389/fimmu.2022.885672
_version_ 1784739529433808896
author Mosch, Romy
Guchelaar, Henk-Jan
author_facet Mosch, Romy
Guchelaar, Henk-Jan
author_sort Mosch, Romy
collection PubMed
description The use of monoclonal antibodies (mAbs) in the clinic has successfully expanded to treatment of cancer, viral infections, inflammations, and other indications. However, some of the classes of mAbs that are used in the clinic show the formation of anti-drug antibodies (ADAs) leading to loss of efficacy. This review describes ADA formation for the various mAbs, and its clinical effect. Lastly, this review considers the use of HLA-haplotypes as biomarkers to predict vulnerability of patients sensitive to formation of ADAs.
format Online
Article
Text
id pubmed-9249215
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92492152022-07-02 Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients Mosch, Romy Guchelaar, Henk-Jan Front Immunol Immunology The use of monoclonal antibodies (mAbs) in the clinic has successfully expanded to treatment of cancer, viral infections, inflammations, and other indications. However, some of the classes of mAbs that are used in the clinic show the formation of anti-drug antibodies (ADAs) leading to loss of efficacy. This review describes ADA formation for the various mAbs, and its clinical effect. Lastly, this review considers the use of HLA-haplotypes as biomarkers to predict vulnerability of patients sensitive to formation of ADAs. Frontiers Media S.A. 2022-06-17 /pmc/articles/PMC9249215/ /pubmed/35784343 http://dx.doi.org/10.3389/fimmu.2022.885672 Text en Copyright © 2022 Mosch and Guchelaar https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Mosch, Romy
Guchelaar, Henk-Jan
Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients
title Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients
title_full Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients
title_fullStr Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients
title_full_unstemmed Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients
title_short Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients
title_sort immunogenicity of monoclonal antibodies and the potential use of hla haplotypes to predict vulnerable patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249215/
https://www.ncbi.nlm.nih.gov/pubmed/35784343
http://dx.doi.org/10.3389/fimmu.2022.885672
work_keys_str_mv AT moschromy immunogenicityofmonoclonalantibodiesandthepotentialuseofhlahaplotypestopredictvulnerablepatients
AT guchelaarhenkjan immunogenicityofmonoclonalantibodiesandthepotentialuseofhlahaplotypestopredictvulnerablepatients

Ejemplares similares